2nd Quarter - Report

OGR for AMGEN USA INC

Firm
OGR
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part D and Medicare Part B reimbursement and coverage issues. H.R.3, Lower Drug Costs Now Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.2693, To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement. S.283, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019.

LobbyistCovered position, as disclosed
DEAN AGUILLEN —
MOSES MERCADO —
KARISSA WILLHITE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (116th), H.R. 2693 (116th), S. 2543 (116th), S. 283 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.